This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
HRC or BLFS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRC vs. BLFS: Which Stock Is the Better Value Option?
HRC vs. BLFS: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. BLFS: Which Stock Is the Better Value Option?
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 0.00% and 9.67%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
HRC vs. BLFS: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. BLFS: Which Stock Is the Better Value Option?
HRC vs. BLFS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HRC vs. BLFS: Which Stock Is the Better Value Option?
3 Soaring MedTech Stocks That Might Lose Ground in 2021
by Trina Mukherjee
Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.
Should You Buy BioLife (BLFS) Ahead of Earnings?
by Zacks Equity Research
BioLife (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Moving Average Crossover Alert: BioLife Solutions
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
BioLife (BLFS) Catches Eye: Stock Jumps 12.1%
by Zacks Equity Research
BioLife (BLFS) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.
Why Earnings Season Could Be Great for BioLife Solutions (BLFS)
by Zacks Equity Research
BioLife Solutions (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Aurora Cannabis (ACB) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) fiscal third-quarter results likely to reflect solid prospects in the Canadian market.
What's in the Cards for SmileDirectClub's (SDC) Q1 Earnings?
by Zacks Equity Research
SmileDirectClub's (SDC) first-quarter performance is likely to reflect benefits from international presence and product development.
Daqo New Energy (DQ) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Our proven model does not conclusively predict an earnings beat for Daqo New Energy (DQ) this season.
Medical Products Industry Outlook: Prospects Seem Promising
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
BioLife Solutions (BLFS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
BioLife (BLFS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioLife Solutions (BLFS) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioLife (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker's (SYK) strong guidance for the first quarter of 2019 buoys optimism in the stock.
Medical Products Industry Gathering Steam: 3 Stocks to Buy
by Nabaparna Bhattacharya
The Medical Products market is gaining traction from a firm exposure to robotics, medical mechatronics and the bipartisan two-year suspension of a 2.3% excise tax on MedTech manufacturers.
BioLife (BLFS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
BioLife (BLFS) is likely to gain from solid segmental revenues in Q3.
What's in Store for AmerisourceBergen (ABC) in Q4 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to be driven by its core Pharmaceutical Distribution business despite a competitive industry.
What's in Store for Quidel (QDEL) This Earnings Season?
by Zacks Equity Research
Strong growth in Cardiac Immunoassay segment's revenues is likely to drive Quidel's (QDEL) top line in Q3.
Can Solid European Sales Boost Inogen (INGN) in Q3 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in the third quarter. However, the decline in rental revenues is a concern.
BioLife Solutions (BLFS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioLife (BLFS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioLife Solutions Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
BioLife Solutions has been struggling lately, but the selling pressure may be coming to an end soon.